GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Shares Outstanding (Basic Average)

Avalo Therapeutics (Avalo Therapeutics) Shares Outstanding (Basic Average) : 0.86 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Avalo Therapeutics's average basic shares outstanding for the quarter that ended in Mar. 2024 was 0.86 Mil.


Avalo Therapeutics Shares Outstanding (Basic Average) Historical Data

The historical data trend for Avalo Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Shares Outstanding (Basic Average) Chart

Avalo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.04 0.04 0.28

Avalo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.20 0.80 0.86

Avalo Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Avalo Therapeutics  (NAS:AVTX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Avalo Therapeutics Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.
Executives
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd. 10 percent owner PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan officer: Interim CFO C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil officer: Chief Medical Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan director C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski officer: Chief Commercial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson director 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller director C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway officer: CFO & Treasurer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins officer: Chief Medical Officer 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr officer: Chief Commercial Officer C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022